PARP1 and Miyoshi myopathy: Indeed, previous studies have shown that following treatment of MM patients with high-dose melphalan (HDM) and autologous stem cell transplantation (ASCT), higher expressions of BRCA1, PRKDC (DNA-PK), and PARP1 genes are linked to poorer outcomes [43].